X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (34) 34
humans (27) 27
cell biology (19) 19
dna damage (19) 19
phosphorylation (16) 16
cell cycle (15) 15
chk (15) 15
animals (14) 14
cancer (14) 14
apoptosis (13) 13
oncology (13) 13
biochemistry & molecular biology (12) 12
checkpoint kinase 1 (11) 11
signal transduction (11) 11
activation (10) 10
cell cycle proteins - metabolism (9) 9
protein-serine-threonine kinases - metabolism (9) 9
cell line, tumor (8) 8
checkpoint kinase 2 (8) 8
kinases (8) 8
protein kinases - metabolism (8) 8
mice (7) 7
p53 (7) 7
proteins (7) 7
ataxia telangiectasia mutated proteins (6) 6
atm (6) 6
chk tyrosine kinase (6) 6
dna-binding proteins - metabolism (6) 6
expression (6) 6
gene expression (6) 6
hela cells (6) 6
mitosis (6) 6
protein kinase inhibitors - pharmacology (6) 6
tumor suppressor protein p53 - metabolism (6) 6
tumor suppressor proteins - metabolism (6) 6
antineoplastic agents - pharmacology (5) 5
cell line (5) 5
cell proliferation (5) 5
checkpoint (5) 5
chk 1 (5) 5
chk1 protein (5) 5
cyclin b1 (5) 5
deoxyribonucleic acid--dna (5) 5
biochemistry (4) 4
biology (4) 4
blotting, western (4) 4
calcium (4) 4
cell division (4) 4
cell-cycle (4) 4
chk, checkpoint kinase (4) 4
chk1 (4) 4
cycle (4) 4
dna repair (4) 4
dna-damage (4) 4
down-regulation (4) 4
inhibition (4) 4
mammalian-cells (4) 4
molecular biology (4) 4
replication (4) 4
research (4) 4
tumor cells, cultured (4) 4
tumors (4) 4
analysis (3) 3
apoptosis - genetics (3) 3
binding (3) 3
biology and life sciences (3) 3
biophysics (3) 3
bioscience (3) 3
breast cancer (3) 3
cancer cells (3) 3
care and treatment (3) 3
cell (3) 3
cell cycle - drug effects (3) 3
checkpoint kinase 2 - metabolism (3) 3
chk2 (3) 3
chk2 protein (3) 3
combination (3) 3
dna-binding proteins - genetics (3) 3
dna-damage response (3) 3
double-strand breaks (3) 3
female (3) 3
gemcitabine (3) 3
genetic aspects (3) 3
genetics (3) 3
genomes (3) 3
hematology (3) 3
in-vivo (3) 3
ionizing-radiation (3) 3
landes (3) 3
life sciences (3) 3
mapk, mitogen-activated protein kinase (3) 3
mitosis - drug effects (3) 3
organogenesis (3) 3
pkb, protein kinase b (3) 3
pkc, protein kinase c (3) 3
protein kinases - physiology (3) 3
protein-serine-threonine kinases - antagonists & inhibitors (3) 3
protein-serine-threonine kinases - genetics (3) 3
s-phase (3) 3
s-phase checkpoint (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Cellular and Molecular Medicine, ISSN 1582-1838, 10/2013, Volume 17, Issue 10, pp. 1261 - 1270
Journal Article
Biochemical Journal, ISSN 0264-6021, 12/2007, Volume 408, Issue 3, pp. 297 - 315
The specificities of 65 compounds reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein kinases.... 
Drug discovery | Kinase profiling | Protein kinase | Anti-cancer drugs | Inhibitor specificity | RHO-ASSOCIATED KINASE | TUMOR PROGRESSION | FAMILY-MEMBERS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL-PROLIFERATION | protein kinase | P38 MAP KINASE | CYCLIN-DEPENDENT KINASES | RECEPTOR TYROSINE KINASES | drug discovery | kinase profiling | SB 203580 | anti-cancer drugs | ISOFORMS IN-VITRO | P90 RSK | inhibitor specificity | Amino Acid Sequence | Cell Line | Phosphorylation | Recombinant Proteins - antagonists & inhibitors | Animals | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Humans | Drug Design | Protein Kinase Inhibitors - pharmacology | Enzyme Activation | Mitogen-Activated Protein Kinases - metabolism | Spodoptera | Index Medicus | Yes1, Yamaguchi sarcoma viral oncogene homologue 1 | CSK, C-terminal Src kinase | Lck, lymphocyte cell-specific protein-tyrosine kinase | EGF, epidermal growth factor | FGF-R, fibroblast-growth-factor receptor | PAK, p21-activated protein kinase | PDK, 3-phosphoinositide-dependent protein kinase | PI3K, phosphatidylinositol (phosphoinositide) 3-kinase | NEK, NIMA (never in mitosis in Aspergillus nidulans)-related kinase | RSK, p90 ribosomal S6 kinase | HEK-293 cells, human embryonic kidney-293 cells | VEGF, vascular endothelial growth factor (vasoendothelial growth factor) | EF2K, elongation-factor-2 kinase | CK, casein kinase | PTEN, phosphatase and tensin homologue deleted on chromosome 10 | ERK, extracellular-signal-regulated kinase | ATM, ataxia telangiectasia mutated | SRPK, serine-arginine protein kinase | IL-1, interleukin 1 | MNK, MAPK-integrating protein kinase | ROCK, Rho-dependent protein kinase | CaMKK, CaMK kinase | GST, glutathione transferase | MKK1, MAPK kinase-1 (also called MEK1, MAPK or ERK kinase 1) | GAK, cyclin G-associated kinase | FMK, fluoromethylketone | MST, mammalian homologue Ste20-like kinase | PKA, cAMP-dependent protein kinase | FKBP, FK506-binding protein | PPAR, peroxisome-proliferator-activated receptor | IKK, inhibitory κB kinase | PH, pleckstrin homology | MBP, myelin basic protein | AICAR, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside | MAPKAP-K, MAPK-activated protein kinase | Sf21, Spodoptera frugiperda (fall armyworm) 21 | MARK, microtubule-affinity-regulating kinase | PIM, provirus integration site for Moloney murine leukaemia virus | LPS, lipopolysaccharide | MSK, mitogen- and stress-activated protein kinase | MAPK, mitogen-activated protein kinase | MELK, maternal embryonic leucine-zipper kinase | His6, hexahistidine | CAK, cyclin-dependent kinase-activating kinase | Eph-A2, Ephrin A2 receptor | PLK, polo-like kinase | ATF2, activating transcription factor 2 | PKD, protein kinase D | Src, sarcoma kinase | AMPK, AMP-activated protein kinase | MMS, methyl methanesulfonate | CHK, checkpoint kinase | JNK, c-Jun N-terminal kinase | TORC1, mTOR (mammalian target of rapamycin)–raptor (regulatory associated protein of mTOR) complex | BRSK, brain-specific kinase | RIP2, receptor-interacting protein 2 | IGF-1, insulin-like growth factor-1 | S6K1, S6 kinase 1 | DYRK, dual-specificity tyrosine-phosphorylated and -regulated kinase | HIPK, homeodomain-interacting protein kinase | ZMP, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside monophosphate | PRAK, p38-regulated activated kinase | PKC, protein kinase C | Src-I1, Src inhibitor 1 | TANK, TRAF (tumour-necrosis-factor-receptor-associated factor)-family-member-associated nuclear factor κB activator | NFAT, nuclear factor for activated T-cells | PHK, phosphorylase kinase | GSK3, glycogen synthase kinase 3 | PKB, protein kinase B (also called Akt) | CaMK, calmodulin-dependent kinase | CDK, cyclin-dependent protein kinase | NDRG, N-myc downstream-regulated gene | SmMLCK, smooth-muscle myosin light-chain kinase | TBK1, TANK-binding kinase 1 | PRK, protein kinase C-related kinase | SGK, serum- and glucocorticoid-induced kinase
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 09/2013, Volume 12, Issue 9, pp. 1860 - 1873
Despite the use of multimodality therapy using cisplatin to treat patients with advanced stage squamous cell carcinoma of the head and neck (HNSCC), there is... 
DNA-DAMAGING AGENTS | ONCOLOGY | INDUCED APOPTOSIS | MITOTIC CATASTROPHE | IN-VIVO | BETA-GALACTOSIDASE | TUMOR-CELLS | TP53 MUTATIONS | INDUCED SENESCENCE | SQUAMOUS CARCINOMA-CELLS | CHECKPOINT KINASE INHIBITOR | Protein Kinases - metabolism | Thiophenes - therapeutic use | Mitosis | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Cellular Senescence - drug effects | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Head and Neck Neoplasms - metabolism | Tumor Suppressor Protein p53 - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Checkpoint Kinase 2 - metabolism | Urea - analogs & derivatives | Antineoplastic Agents - pharmacology | Signal Transduction | Head and Neck Neoplasms - drug therapy | Tumor Suppressor Protein p53 - metabolism | Thiophenes - pharmacology | Cisplatin - pharmacology | Head and Neck Neoplasms - pathology | Drug Resistance, Neoplasm - genetics | Urea - therapeutic use | Carcinoma, Squamous Cell - drug therapy | Cisplatin - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Checkpoint Kinase 1 | Head and Neck Neoplasms - genetics | Protein Kinase Inhibitors - pharmacology | DNA Damage | Mutation | Urea - pharmacology | Index Medicus | senescence | apoptosis | p53 mutation | Chk kinases | cisplatin
Journal Article
RADIOTHERAPY AND ONCOLOGY, ISSN 0167-8140, 09/2004, Volume 72, Issue 3, pp. 305 - 310
Background and purpose: The tumor cell defense response to ionizing radiation involves a temporary arrest at the cell cycle G(2) checkpoint, which is activated... 
APOPTOSIS | cell cycle | CHK | BRCA1 | PLK | P53 | DNA-DAMAGE CHECKPOINT | ONCOLOGY | LINE | molecular targeting | radiotherapy | AGENTS | IONIZING-RADIATION | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | gene expression
Journal Article
FEBS Letters, ISSN 0014-5793, 2001, Volume 496, Issue 1, pp. 44 - 48
The specificity of 4,5,6,7‐tetrabromo‐2‐azabenzimidazole (TBB), an ATP/GTP competitive inhibitor of protein kinase casein kinase‐2 (CK2), has been examined... 
Casein kinase | Inhibitor | Casein kinase-2 | Protein phosphorylation | Protein kinase | nCK, native casein kinase | OA, okadaic acid | PRAK, p38-regulated/activated kinase | CSK, C-terminal Src kinase | AMPK, AMP-activated protein kinase | CHK, checkpoint kinase | JNK, c-Jun N-terminal kinase | MAPKAP, MAPK-activated protein kinase | p70S6K, p70 ribosomal protein S6 kinase | CK, casein kinase | SAPK, stress-activated protein kinase | PDK, 3-phosphoinositide-dependent kinase | DRB, 1-(β | ROCK, Rho-dependent protein kinase | CDK, cyclin-dependent kinase | G-CK, Golgi casein kinase | PKC, protein kinase C | MKK, MAPK kinase (also called MEK) | ribofuranosyl)-5,6-dichlorobenzimidazole | PKA, cAMP-dependent protein kinase | PHK, phosphorylase kinase | GSK3, glycogen synthase kinase 3 | PKB, protein kinase B (also called Akt) | rCK, recombinant casein kinase | ERK, extracellular signal-regulated kinase | HS1, hematopoietic lineage cell-specific protein 1 | MSK, mitogen- and stress-activated protein kinase | TBB, 4,5,6,7-tetrabromo-2-azabenzimidazole or 4,5,6,7-tetrabromobenzotriazole | MAPK, mitogen-activated protein kinase | SGK, serum- and glucocorticoid-induced kinase | CATALYTIC SUBUNIT | ZEA-MAYS | TYROSINE KINASE | CRYSTAL-STRUCTURE | COMPETITIVE INHIBITOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | protein phosphorylation | IMMUNOPHILIN FPR3 | SACCHAROMYCES-CEREVISIAE | protein kinase | CELL BIOLOGY | casein kinase | BIOPHYSICS | inhibitor | CELL-CYCLE | BETA-SUBUNIT | casein kinase-2 | MAMMARY-GLAND | Protein Kinases - metabolism | Jurkat Cells - cytology | Protein Kinases - drug effects | Casein Kinase II | Emodin - pharmacology | Jurkat Cells - metabolism | Humans | Enzyme Inhibitors - pharmacology | Protein-Serine-Threonine Kinases - genetics | Substrate Specificity | Adenosine Triphosphate | Binding Sites - genetics | Binding, Competitive - drug effects | Triazoles - pharmacology | Triazoles - metabolism | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Binding Sites - drug effects | Protein-Serine-Threonine Kinases - metabolism | Staurosporine - pharmacology | Amino Acid Substitution | Jurkat Cells - drug effects | Index Medicus
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, pp. e0171860 - e0171860
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 04/2012, Volume 13, Issue 6, pp. 379 - 388
Journal Article